アルドステロン塩で治療されたラットにおける頸動脈壁の弾性モジュールとフィブロネクチンの増加:エプレレノンによる効果
Patrick Lacolley1, Carlos Labat, Alex Pujol
1INSERM EMI U0107, Paris, France.
Circulation
|November 27, 2002
まとめ
アルドステロンは,壁のストレスとは関係なく,ネズミの動脈の硬化とフィブロネクチンの蓄積を増加させます. エプレレノンはこれらの変化を防止し,血管の変化におけるミネラルコルチコイド受容体の関与を示しています.
科学分野:
- 心血管生理学 心血管の生理学
- 薬理学 薬理学とは
- 血管生物学 血管生物学
背景:
- アルドステロン (アルド) 塩による高血圧は,心筋線維症と関連しています.
- 大動脈のメカニズムに対するアルドの影響を調査することは極めて重要です.
研究 の 目的:
- Aldoとeplerenone (Epl) の in vivo 頸動脈の機械的性質への影響を決定する.
- アルドによる血管の変化におけるミネラルコルチコイド受容体の役割を評価する.
主な方法:
- アルド塩高血圧ラットモデルが確立されました.
- エコー・トラッキング・システムは,in vivoの弾性測定に使用されます.
- 動脈壁の構造は,ヒストモルフォメトリーと免疫ヒスト化学で分析された.
主要な成果:
- アルドは動脈の硬さ (Einc),脈圧,およびフィブロネクチン (Fn) の蓄積を増加させた.
- エプレレノンの投与量によって動脈の硬さが正常化し,フィブロネクチンが減少した.
- これらの効果は,壁の張力やコラーゲン/エラスティンの密度の変化なしに発生しました.
結論:
- アルドステロンは,壁のストレスとは無関係に動脈の硬化とフィブロネクチンの蓄積を誘発する.
- エプレレノンの予防効果は,血管の再構築におけるミネラルコルチコイド受容体の役割を強調しています.
- 発見は,ハイパーアルドステロン症に誘発された血管機能不全の直接的受容体媒介メカニズムを示唆しています.
関連する概念動画
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...